Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2026-01-20 @ 8:51 AM
Study NCT ID:
NCT03430895
Status:
COMPLETED
Last Update Posted:
2021-12-01
First Post:
2018-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-01-31
Start Date Type:
ACTUAL
Primary Completion Date:
2021-02-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-02-10
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-07
First Submit QC Date:
None
Study First Post Date:
2018-02-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-11-03
Results First Submit QC Date:
None
Results First Post Date:
2021-12-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-03
Last Update Post Date:
2021-12-01
Last Update Post Date Type:
ACTUAL